Qualico Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Qualico Pharma
Largest movements
- Cash +€85,161
up €85,161 (+43719.5%), from €195 to €85,356
mainly Net result for the year (+€65,048) and Tax, wage and social debts (+€19,106)
- Receivables within one year +€10,426
up €10,426 (+48.1%), from €21,680 to €32,106
of which Trade receivables: +€7,526
- Tangible fixed assets +€2,080
new in 2025: €2,080
- Deferred charges and accrued income +€1,970
new in 2025: €1,970
- Profit (loss) carried forward +€64,215
new in 2025: €64,215
- Tax, wage and social debts +€19,106
up €19,106 (+337.8%), from €5,656 to €24,762
- Trade debts +€8,245
up €8,245 (+1407.6%), from €586 to €8,830
- Other debts +€8,130
up €8,130 (+703.0%), from €1,156 to €9,286
- Gross operating margin +€66,210
up €66,210 (+382.3%), from €17,318 to €83,528
- Taxes +€12,408
up €12,408 (+274.7%), from €4,518 to €16,925
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €21,875 | €121,569 | +€99,694 | +455.8% |
| Fixed assets | 21/28 | - | €2,138 | +€2,138 | |
| Tangible fixed assets | 22/27 | - | €2,080 | +€2,080 | |
| Furniture and vehicles | 24 | - | €2,080 | +€2,080 | |
| Financial fixed assets | 28 | - | €57 | +€57 | |
| Current assets | 29/58 | €21,875 | €119,432 | +€97,557 | +446.0% |
| Amounts receivable within one year | 40/41 | €21,680 | €32,106 | +€10,426 | +48.1% |
| Trade receivables | 40 | €21,680 | €29,206 | +€7,526 | +34.7% |
| Other amounts receivable | 41 | €0 | €2,900 | +€2,900 | |
| Cash at bank and in hand | 54/58 | €195 | €85,356 | +€85,161 | +43719.5% |
| Deferred charges and accrued income | 490/1 | - | €1,970 | +€1,970 | |
| Total equity and liabilities | 10/49 | €21,875 | €121,569 | +€99,694 | +455.8% |
| Equity | 10/15 | €14,477 | €78,691 | +€64,215 | +443.6% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €11,477 | €11,477 | = | 0.0% |
| Distributable reserves | 133 | €11,477 | €11,477 | = | 0.0% |
| Profit (loss) carried forward | 14 | - | €64,215 | +€64,215 | |
| Amounts payable | 17/49 | €7,398 | €42,878 | +€35,480 | +479.6% |
| Amounts payable within one year | 42/48 | €7,398 | €42,878 | +€35,480 | +479.6% |
| Trade debts | 44 | €586 | €8,830 | +€8,245 | +1407.6% |
| Suppliers | 440/4 | €586 | €8,830 | +€8,245 | +1407.6% |
| Taxes, remuneration and social security | 45 | €5,656 | €24,762 | +€19,106 | +337.8% |
| Taxes | 450/3 | €5,656 | €24,762 | +€19,106 | +337.8% |
| Other amounts payable | 47/48 | €1,156 | €9,286 | +€8,130 | +703.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €504 | +€504 | |
| Other operating charges | 640/8 | €486 | €781 | +€295 | +60.6% |
| Gross operating margin | 9900 | €17,318 | €83,528 | +€66,210 | +382.3% |
| Operating profit (loss) | 9901 | €16,831 | €82,243 | +€65,411 | +388.6% |
| Financial charges | 65/66B | €4 | €270 | +€266 | +6431.5% |
| Recurring financial charges | 65 | €4 | €270 | +€266 | +6431.5% |
| Profit (loss) for the period before taxes | 9903 | €16,827 | €81,973 | +€65,146 | +387.1% |
| Income taxes | 67/77 | €4,518 | €16,925 | +€12,408 | +274.7% |
| Profit (loss) for the period | 9904 | €12,310 | €65,048 | +€52,738 | +428.4% |
| Profit (loss) for the period to be appropriated | 9905 | €12,310 | €65,048 | +€52,738 | +428.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.